The Institute for Clinical and Economic Review (ICER) has released a Draft Evidence Report evaluating the clinical effectiveness and relative value—including value-based price benchmarks—of 11 rheumatoid arthritis therapies.1 All interested parties were given the opportunity to submit formal comments regarding the report and the draft voting questions to ICER by February 17, 2017. A version of the Draft Evidence Report with accompanying voting questions that includes any changes made based on feedback received during the public comment period will be posted to the ICER website on or around March 10, 2017, along with all of the comments that were submitted.
On March 24, 2017, this report will be the topic of a free, public meeting held by the New England Comparative Effectiveness Public Advisory Council, a nationally recognized community forum and core program of ICER, in Boston, MA. During this meeting, recommendations that can be translated to policy and practice in the field of rheumatology will be deliberated by an expert policy roundtable, and the New England Comparative Effectiveness Public Advisory Council will vote on important questions brought up in the Draft Evidence Report. There will also be a limited time frame allotted at this public meeting for attendees to make oral comments in response to the report. Clinicians, payers, and patients who wish to attend the meeting or watch it live via webcast can register at www.eventbrite.com/e/new-england-cepac-meeting-treatments-for-rheumatoid-arthritis-tickets-31259846041.
- Institute for Clinical and Economic Review. ICER releases draft evidence report on treatments for rheumatoid arthritis. January 20, 2017. https://icer-review.org/announcements/ra-draft-report/. Accessed February 14, 2017.